UbiVac is a biotechnology company developing and commercializing immunotherapy products that induce anti-cancer immunity. It offers DRibble immunotherapy, the technology that combines cancer targets, including cancer antigens, together with immune stimulants, a spectrum of heat shock proteins, and chaperones.